Celularity Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CELU Nasdaq 8731

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Celularity Inc

Correcting & Replacing -- Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) - Feb 2nd, 2023 12:53 pm
Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) - Feb 1st, 2023 9:05 pm
Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates - Jan 26th, 2023 9:17 pm
Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East - Jan 11th, 2023 6:35 pm
Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia - Jan 11th, 2023 6:22 pm
Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies - Jan 6th, 2023 1:10 pm
Celularity Appoints Paul Graves as Chief Communications Officer - Jan 4th, 2023 9:10 pm
Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model - Dec 5th, 2022 1:00 pm
Celularity CEO Robert J. Hariri, M.D., Ph.D., Addresses FII Conference on "The Science and Technology for Extending Healthy Human Lifespan" - Nov 30th, 2022 2:55 pm
Imugene’s onCARlytics combination with Celularity’s placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting - Nov 10th, 2022 10:00 pm
Celularity Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 10th, 2022 9:10 pm
Celularity Presents Preclinical Data on CYNK-101, its Allogeneic Genetically-Modified Natural Killer Cell Therapy Candidate, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting - Nov 10th, 2022 2:10 pm
Celularity Promotes Two Executives in Executive Leadership Team - Oct 6th, 2022 12:00 pm
Celularity Appoints Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer - Oct 3rd, 2022 12:00 pm
Celularity to Present at Jefferies Cell and Genetic Medicine Summit - Sep 27th, 2022 12:00 pm
Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro - Sep 26th, 2022 12:00 pm
Celularity Enters Into $150 Million Pre-Paid Advance Agreement with Yorkville - Sep 15th, 2022 6:29 pm
Celularity Announces Participation in Upcoming Investor Conferences - Sep 6th, 2022 8:10 pm
Celularity Reports Second Quarter 2022 Financial Results and Corporate Update - Aug 9th, 2022 8:10 pm
Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers - Jul 27th, 2022 12:00 pm